Try EV is a platform that allows customers to discover, analyze, customize and explore with EVs before making a final buying decision. It encourages “electrify to buy” and intends to change the car purchasing process. The company has also collaborated with big brands such as BMW, Tesla, etc. Try Ev was an Exhibitor at London Motor Show 2019, it was shortlisted for “Greener Greenwich” at Greenwich Business Awards and it was an Elevator Pitch Business Awards finalists at London Motor Show 2018. The funds will be used to balance the growth, to bring key talent, to promote partnerships with major leasing companies and charging networks and to improve marketing and promotion efforts.
days to go:
Expired
investment:
£88,430
EnXray are developing Low Energy X-ray (LEXR) technologies to sterilise equipment in commercial or research settings where low volume/high value therapeutic products, such as cancer vaccines and stem cell implants are being developed. Their aim is to reduce the need for third party providers and have the sterilisation process done on-site and on-demand with simple and safe equipment to reduce cost and save time for medical research organisations.
days to go:
Expired
investment:
£376,230
TC BioPharm is an immunotherapy company. It has used its patented technology to harness the power of a particular part of the immune system, Gamma Delta T-cells (GDT), to negate cancer cells in the human body. TC BioPharm has treated terminally ill patients with acute myeloid leukaemia in approved clinical trials garnering positive responses from multiple patients. The company has received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to run a COVID-19 clinical trial to address the global pandemic. TC BioPharm aims to use its current technology to provide a frozen product that can be manufactured cost-effectively and distributed globally. The company has already raised over £7 million in the last 15 months. It will use the investment to take its clinical trials forward in COVID-19 and cancer.
days to go:
Expired
investment:
£1,753,067
Carverter is a technology platform that enables customers to find and lease a hybrid or Electric Vehicle (EV). The company cites data pointing out the UK government's ban on the sale of petrol and diesel only cars after 2030. It also argues about changing car preferences, with 78% of consumers considering leasing to access an EV. Carverter aims to capture this audience and grow its business. The company uses its algorithm to bring together over 32 million data points across its three tools, namely Carvert, Carwizard, and Browse, to help users find their choice of hybrid/EV. Carverter has partnered with renowned entities like WPP, Arval, Microsoft & ITV to boost its business. It will use 10% of the investment on hiring staff, 20% towards rolling out its services across 22 European countries via Arval, and 70% on an advertising multiplier deal with the UK's largest commercial broadcaster, ITV, and WPP.
days to go:
Expired
investment:
£2,324,693
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.
days to go:
Expired
investment:
£211,595
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.
days to go:
Expired
investment:
£270,543
WhyBuy is a rental platform that allows a user to rent out items or entities he/she may want to another person. WhyBuy asserts that consumers want to be able to access items for brief periods, and the company aims to be the go-to provider in this segment. It endeavours to save time, space, money and the environment through its business model that is backed by a 100% electric delivery fleet. The company has tested its supply chain to ensure orders are placed despite COVID-19 restrictions. Its app has seen 8000+ downloads from mid-June to end-July 2020 at just over £3 per acquired download across the App Store and Google Playstore. It will use 75% of the investment for marketing, 5% to expand its electric fleet, and 15% as stock and overhead expenses.
days to go:
Expired
investment:
£309,260
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.
days to go:
Expired
investment:
£200,000
MedicSpot is a healthcare company that is aiming to revolutionise healthcare delivery by combining the advantages of online and offline care. The company provides patients at designated hospitals with diagnostic tools like a stethoscope, oximeter, blood pressure monitor and thermometer which, in turn, is connected to the MedicSpot network. Onboard General Physicians (GPs) engage in live sessions with patients, guide them on how to use the tools, and perform a variety of diagnoses like listening to a patient’s heart and lungs, looking down their throat and into their ears, taking their blood pressure and oxygen readings, and measuring their body temperature. The company is also expanding into another subsidiary, Arc Health, which it claims will perform the aforementioned tasks with more efficiency and accuracy. The company will use the investment to increase the number of Medicspot clinics to 1,000, gain further NHS market share, launch a corporate business model and allow international pilots to take place.
days to go:
Expired
investment:
£1,048,396
Quin is a mobile medical app that combines daily life experience with data from diabetes devices and phones and helps people decide how much insulin to take and when. They are on a mission to help people with insulin-treated diabetes make the best possible decisions through their app. The company have received a UK research and innovation grant. Apple has granted them insider access to their engineers and executives who are helping to get Quin to market, their app has a class I CE Mark, with two patents pending. With the investment, they will hire a product designer to enhance the user experience, achieve certification and compliance with new European Medical Device Regulations, develope B2B2C distribution partnerships and launch the Quin app in the UK and Europe in late 2020.
days to go:
Expired
investment:
£691,497
